Cargando…

Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Ramayya, Tarun, Mitchell, Joshua D., Hartupee, Justin C., Lavine, Kory, Ridley, Clare H., Kotkar, Kunal D., Jimenez, Jesus, Lin, Chieh-Yu, Alvarez-Cardona, Jose A., Krone, Ronald K., Campbell, Courtney M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Clinical Case Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830207/ https://www.ncbi.nlm.nih.gov/pubmed/36636445 http://dx.doi.org/10.1016/j.jaccao.2022.08.013

Ejemplares similares

Fulminant myocarditis in COVID-19 and favorable outcomes with VA-ECMO
por: Bhardwaj, Abhishek, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Case report: VA-ECMO for fulminant myocarditis in an infant with acute COVID-19
por: Hsu, Hao-Ting, et al.
Publicado: (2023)

Reverse TakoTsubo or Fulminant myocarditis ? Life saving VA ECMO in a COVID 19 patient
por: Hamdan, Righab, et al.
Publicado: (2022)

Cardiogenic Shock in COVID 19 Fulminant Myocarditis Treated with V-A ECMO
por: D'Errico Ramirez, A., et al.
Publicado: (2022)

ECMO as an effective rescue therapeutic for fulminant myocarditis complicated with refractory cardiac arrest
por: Li, Ya-Ting, et al.
Publicado: (2017)

Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients
por: Yeung, Timothy, et al.
Publicado: (2022)

Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation
por: Nguyen, Andrew T., et al.
Publicado: (2022)

Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance
por: Jimenez, Jesus, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression
por: Liu, Shiying, et al.
Publicado: (2020)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
por: Mirabel, Mariana, et al.
Publicado: (2020)

Successful treatment of intracardiac thrombosis in the presence of fulminant myocarditis requiring ECMO associated with COVID-19
por: Mejia, Erika J., et al.
Publicado: (2022)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Nursing effect of ECMO combined with CRRT in the treatment of fulminant myocarditis: A protocol of randomized controlled trial
por: Wu, Juan, et al.
Publicado: (2021)

Neonatal VA ECMO: Why and how?
por: Mendonca, Malaika
Publicado: (2017)

Surgical pulmonary embolectomy on VA-ECMO
por: Steinhorn, Rachel, et al.
Publicado: (2021)

Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells
por: Koch, Christian, et al.
Publicado: (2022)

Early characteristics of fulminant myocarditis vs non-fulminant myocarditis: A meta-analysis
por: Wang, Zicheng, et al.
Publicado: (2019)

Microcirculatory assessment of patients under VA-ECMO
por: Kara, Atila, et al.
Publicado: (2016)

Postcardiotomy VA-ECMO for refractory cardiogenic shock
por: Charlesworth, Michael, et al.
Publicado: (2017)

LV distention on VA-ECMO, what to do?
por: Pappalardo, Federico, et al.
Publicado: (2017)

Levosimendan for VA‐ECMO weaning: the silver lining
por: Kaddoura, Rasha, et al.
Publicado: (2021)

Growing Evidence for LV Unloading in VA ECMO
por: Soltes, Jan, et al.
Publicado: (2023)

Fulminant myocarditis in the time of coronavirus
por: Cuomo, Vittoria, et al.
Publicado: (2020)

Fulminant myocarditis and COVID-19
por: Joob, Beuy, et al.
Publicado: (2020)

COVID-Induced Fulminant Myocarditis
por: Rodriguez Guerra, Miguel A, et al.
Publicado: (2022)

Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
por: Ma, Pan, et al.
Publicado: (2023)

Role of VA ECMO in septic shock: Does it work?
por: Combes, Alain
Publicado: (2017)

A case study of Harlequin syndrome in VA-ECMO
por: Al Hanshi, Said Ali Masoud, et al.
Publicado: (2017)

Predicting clinical outcome in patients undergoing VA-ECMO
por: Kimmoun, Antoine, et al.
Publicado: (2019)

Recurrent Silicone Embolism Syndrome requiring VA ECMO
por: Madan, Nikhil, et al.
Publicado: (2022)

Hidden Harlequin syndrome in neonatal and pediatric VA-ECMO
por: Levy, Yael, et al.
Publicado: (2022)

Predictors of weaning failure in case of VA ECMO implantation
por: Cusanno, Axelle, et al.
Publicado: (2022)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
por: Liu, Zhijie, et al.
Publicado: (2022)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

Transient Myocarditis Associated with Fulminant Colitis
por: Williamson, J. M. L., et al.
Publicado: (2011)

Fulminant Guillain-Barré Syndrome with Myocarditis
por: Mishra, Ajay, et al.
Publicado: (2014)

Fulminant myocarditis: Characteristics, treatment, and outcomes
por: Veronese, Giacomo, et al.
Publicado: (2018)

Consideration on pathogen of viral fulminant myocarditis
por: Wei, Xin, et al.
Publicado: (2020)

Fulminant myocarditis and COVID-19. Response
por: Irabien-Ortiz, Ángela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v8cd8an2dgp9s84a12lgr465f9